Published on

Medicine – Thrombocytopenia

Thrombocytopenia is a haematological condition characterised by a circulating platelet count below 150 × 10⁹/L.

Platelets are essential for primary haemostasis. A reduction in platelet count increases the risk of mucocutaneous bleeding, including petechiae, purpura, epistaxis and gum bleeding.

Important Clinical Principle

Thrombocytopenia results from decreased platelet production, increased destruction or consumption, splenic sequestration, dilution, or laboratory artefact. Identifying the mechanism is essential because management differs substantially between causes.

1. Classification of Thrombocytopenia

Severity Platelet Count
Mild100–149 × 10⁹/L
Moderate50–99 × 10⁹/L
SevereBelow 50 × 10⁹/L
Very severeBelow 10 × 10⁹/L

Spontaneous serious bleeding becomes more likely at very low platelet counts, particularly below 10 × 10⁹/L. However, bleeding risk also depends on platelet function, the underlying disease and other clinical factors.

2. Pathophysiology

The mechanisms of thrombocytopenia can be divided into four principal groups.

Thrombocytopenia Reduced Production Marrow failure B12 / folate deficiency Destruction / Consumption ITP, HIT, DIC TTP / HUS Sequestration Hypersplenism Portal hypertension Dilution / Artefact Massive transfusion Platelet clumping Reduced Circulating Platelet Count

Simplified classification of thrombocytopenia mechanisms. Pseudothrombocytopenia is an artefact rather than true platelet depletion.

3. Decreased Platelet Production

Decreased platelet production occurs when the bone marrow is unable to produce sufficient platelets.

A. Bone Marrow Failure

Bone marrow failure may impair megakaryocyte production and cause thrombocytopenia.

Important Causes

  • Acute leukaemia: Malignant blast cells replace normal haematopoietic tissue.
  • Aplastic anaemia: Reduced production of all three blood cell lines.
  • Myelodysplastic neoplasms: Ineffective and abnormal platelet production.
  • Myelofibrosis: Marrow fibrosis disrupts normal haematopoiesis.
  • Bone marrow infiltration: Lymphoma, multiple myeloma or metastatic carcinoma.
  • Cytotoxic chemotherapy and radiotherapy: Suppression of bone marrow activity.

Thrombocytopenia due to marrow failure is often associated with anaemia or leukopenia.

B. Megaloblastic Anaemia

Vitamin B12 or folate deficiency impairs DNA synthesis and causes ineffective haematopoiesis.

Severe deficiency may result in thrombocytopenia or pancytopenia.

Characteristic Findings

  • Macrocytosis.
  • Macro-ovalocytes.
  • Hypersegmented neutrophils.
  • Reduced platelet count.
Examination Pearl: Thrombocytopenia with macro-ovalocytes and hypersegmented neutrophils suggests megaloblastic anaemia.

C. Other Causes of Reduced Production

  • Chronic alcohol exposure.
  • Certain medications.
  • Viral infections affecting marrow function.
  • Severe nutritional deficiencies.
  • Inherited thrombocytopenia syndromes.

4. Increased Platelet Destruction

Increased platelet destruction may be immune-mediated or non-immune-mediated.

A. Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (ITP), historically called immune thrombocytopenic purpura, is an acquired immune disorder characterised by increased platelet destruction and impaired platelet production.

Autoantibodies target platelet antigens, resulting in increased platelet clearance, particularly by the spleen.

Typical Clinical Findings

  • Isolated thrombocytopenia.
  • Petechiae and purpura.
  • Easy bruising.
  • Epistaxis or gum bleeding.
  • Usually no significant splenomegaly.

ITP is a diagnosis of exclusion. Management depends on bleeding severity, platelet count and clinical circumstances.

Treatment Options

  • Observation in selected patients.
  • Corticosteroids.
  • Intravenous immunoglobulin (IVIG).
  • Thrombopoietin receptor agonists.
  • Other second-line immune-directed therapies.

B. Viral Infections

Viral infections may cause thrombocytopenia through immune-mediated platelet destruction, marrow suppression or increased consumption.

Examples

  • Dengue.
  • HIV.
  • Hepatitis C.
  • Epstein–Barr virus.
  • Cytomegalovirus.
Clinical Pearl: Dengue is an important cause of acute thrombocytopenia in endemic regions. Clinical assessment should include warning signs, haemoconcentration, plasma leakage and bleeding.

C. Drug-Induced Thrombocytopenia

Certain medications may cause immune-mediated platelet destruction or bone marrow suppression.

Examples

  • Heparin.
  • Quinine.
  • Some antibiotics.
  • Certain anticonvulsants.
  • Cytotoxic chemotherapy.

Heparin-Induced Thrombocytopenia (HIT)

HIT is a prothrombotic immune complication associated with antibodies against platelet factor 4–heparin complexes.

Important Features

  • Platelet count often falls by more than 50% from baseline.
  • Typically develops 5–10 days after heparin exposure.
  • Earlier onset may occur with recent prior heparin exposure.
  • Associated with thrombosis rather than predominantly bleeding.
  • The 4Ts score helps estimate the pre-test probability.
Important Clinical Warning

Suspected HIT requires prompt assessment. When clinical probability is intermediate or high, heparin should be discontinued and appropriate non-heparin anticoagulation considered under specialist guidance while confirmatory testing is arranged.

D. Systemic Lupus Erythematosus (SLE)

SLE may cause immune-mediated thrombocytopenia through platelet-directed autoantibodies.

Associated manifestations may include:

  • Arthritis.
  • Skin rash.
  • Nephritis.
  • Autoimmune haemolytic anaemia.

E. Lymphoma

Lymphoma may cause thrombocytopenia through several mechanisms:

  • Secondary immune thrombocytopenia.
  • Bone marrow infiltration.
  • Splenic enlargement and sequestration.
  • Treatment-related marrow suppression.

5. Increased Platelet Consumption

A. Disseminated Intravascular Coagulation (DIC)

DIC is a systemic disorder involving widespread activation of coagulation, leading to consumption of platelets and clotting factors.

Common Causes

  • Sepsis.
  • Major trauma.
  • Obstetric complications.
  • Malignancy, particularly acute promyelocytic leukaemia.

Typical Laboratory Findings

  • Thrombocytopenia.
  • Prolonged PT and often aPTT.
  • Elevated D-dimer.
  • Reduced fibrinogen in severe cases.
  • Schistocytes in some patients.

B. Thrombotic Microangiopathy

Thrombotic microangiopathies cause platelet consumption within small-vessel thrombi.

Important Examples

  • Thrombotic thrombocytopenic purpura (TTP).
  • Haemolytic uraemic syndrome (HUS).

Typical findings include:

  • Thrombocytopenia.
  • Microangiopathic haemolytic anaemia.
  • Schistocytes on the peripheral blood film.
  • Possible renal or neurological abnormalities.
Medical Emergency

Suspected TTP requires immediate haematology assessment and urgent treatment. Treatment should not be delayed while awaiting ADAMTS13 results when clinical suspicion is high.

6. Hypersplenism

Hypersplenism causes thrombocytopenia through increased splenic sequestration of platelets.

Important Causes

  • Liver cirrhosis.
  • Portal hypertension.
  • Chronic liver disease.
  • Haematological malignancies.
  • Splenic infiltrative disorders.

Thrombocytopenia is often the earliest or most prominent cytopenia.

Unlike immune destruction, hypersplenism is primarily a problem of platelet distribution, although other mechanisms may coexist.

7. Platelet Aggregation and Pseudothrombocytopenia

Platelet clumping in a blood sample may cause an artificially low automated platelet count.

This is called pseudothrombocytopenia.

It may occur due to EDTA-dependent platelet aggregation in the collection tube.

Important Features

  • The patient may have no bleeding symptoms.
  • Peripheral blood film shows platelet clumps.
  • Repeating the platelet count using an alternative anticoagulant, such as citrate, may help confirm the finding.
Important Distinction: Pseudothrombocytopenia is a laboratory artefact rather than true platelet deficiency. Platelet aggregation in a collection tube must be distinguished from pathological platelet consumption in conditions such as TTP.

8. Clinical Features

Thrombocytopenia typically causes mucocutaneous bleeding, reflecting impaired primary haemostasis.

Clinical Feature Description
PetechiaeSmall, non-blanching red or purple spots
PurpuraLarger areas of bleeding into the skin
EcchymosesBruising
EpistaxisNosebleeds
Gum bleedingBleeding from the oral mucosa
MenorrhagiaHeavy menstrual bleeding
Gastrointestinal bleedingMay occur in severe cases
Intracranial haemorrhageRare but potentially life-threatening

Deep muscle bleeding and haemarthroses are more characteristic of coagulation factor disorders than isolated thrombocytopenia.

9. Investigations

A. Full Blood Count

The full blood count confirms thrombocytopenia and determines whether it is isolated or accompanied by anaemia or leukopenia.

B. Peripheral Blood Film

Blood Film Finding Possible Diagnosis
Isolated low platelets, otherwise normal filmITP
Platelet clumpsPseudothrombocytopenia
SchistocytesTTP, HUS, DIC or another fragmentation process
Circulating blastsAcute leukaemia
Macro-ovalocytes and hypersegmented neutrophilsMegaloblastic anaemia
Dysplastic blood cellsMyelodysplastic neoplasm
Large or giant plateletsITP or inherited macrothrombocytopenia

C. Coagulation Profile

PT, aPTT, fibrinogen and D-dimer may help identify DIC or other coagulation abnormalities.

Coagulation studies are often normal in uncomplicated ITP and TTP.

D. Additional Investigations

  • Liver and renal function tests.
  • Vitamin B12 and folate.
  • HIV, hepatitis and other viral testing when indicated.
  • Autoimmune investigations.
  • Haemolysis markers.
  • HIT testing when indicated.
  • ADAMTS13 activity when TTP is suspected.
  • Bone marrow examination when a marrow disorder is suspected.

10. Diagnostic Approach

Low Platelet Count Assess bleeding and urgency Review Peripheral Blood Film Exclude platelet clumping Assess Associated Findings Isolated or multiple cytopenias? Drugs, infection, splenomegaly Targeted Investigations Coagulation, haemolysis, marrow Identify Underlying Cause Cause-specific management

11. Management

Treatment is directed at the underlying cause rather than the platelet count alone.

Cause General Management
ITPObservation or immune-directed treatment depending on bleeding risk
HITStop heparin and initiate appropriate non-heparin anticoagulation
DICTreat the underlying trigger and provide haemostatic support when indicated
TTPUrgent plasma exchange-based specialist treatment
Megaloblastic anaemiaVitamin B12 or folate replacement as appropriate
Marrow failureDisease-specific treatment and supportive care
HypersplenismTreat the underlying disorder
PseudothrombocytopeniaConfirm the true platelet count; no treatment for the artefact

Platelet Transfusion

Platelet transfusions may be indicated for severe bleeding or selected high-risk situations.

They are not routinely appropriate for all causes of thrombocytopenia, particularly suspected HIT or TTP, where management requires disease-specific assessment.

12. High-Yield Examination Summary

Feature Key Point
DefinitionPlatelets below 150 × 10⁹/L
Reduced productionLeukaemia, aplastic anaemia, megaloblastic anaemia
Immune destructionITP, SLE, drug-induced thrombocytopenia
Heparin-associatedHIT, a prothrombotic condition
Platelet consumptionDIC, TTP, HUS
Splenic sequestrationHypersplenism
Laboratory artefactEDTA-related platelet clumping
Typical bleedingPetechiae, purpura, mucosal bleeding
Key investigationFBC and peripheral blood film
SchistocytesConsider microangiopathic haemolysis
Isolated thrombocytopeniaConsider ITP after excluding other causes

13. Key Examination Pearls

  • Thrombocytopenia is defined as a platelet count below 150 × 10⁹/L.
  • Decreased platelet production occurs in marrow failure and megaloblastic anaemia.
  • ITP typically presents with isolated thrombocytopenia.
  • HIT is associated with thrombosis despite a reduced platelet count.
  • SLE and lymphoma may cause secondary immune thrombocytopenia.
  • DIC and thrombotic microangiopathies cause platelet consumption.
  • Hypersplenism causes platelet sequestration.
  • Platelet clumping can produce pseudothrombocytopenia.
  • Schistocytes with thrombocytopenia raise concern for microangiopathic haemolysis.
  • A peripheral blood film is essential in evaluating an unexplained low platelet count.
Most Important Examination Point

Thrombocytopenia with an otherwise normal blood film suggests possible ITP; thrombocytopenia with schistocytes suggests microangiopathic haemolysis; and thrombocytopenia with anaemia and leukopenia suggests a possible bone marrow disorder.

Clinical Warning

Thrombocytopenia accompanied by active major bleeding, neurological symptoms, suspected TTP, suspected HIT with thrombosis or other signs of serious illness requires urgent medical assessment.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments